FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Börse Stuttgart 06:42:02 2024-06-21 EDT | ||
| 4.1 EUR | -1.20% |
|
| Current month | +10.08% | ||
| 1 month | +9.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 4.1 | -1.20% |
| 24-06-20 | 4.15 | +6.14% |
| 24-06-19 | 3.91 | -5.78% |
| 24-06-18 | 4.15 | -6.74% |
| 24-06-17 | 4.45 | -1.55% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 06:42 am
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | ME23AJ |
| ISIN | DE000ME23AJ5 |
| Date issued | 2023-10-16 |
| Strike | 11,023 p |
| Maturity | Unlimited |
| Parity | 3.84 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.35 € |
|---|---|
| Lowest since issue | 0.73 € |
| Spread | 0.02 € |
| Spread % | 0.44% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.00%
- Stock Market
- Certificates
- Certificat
